After the four innovative drugs are launched, they will fill the gap in the domestic market. Zhangjiangyi Innovative Drug Production Base is put into operation for biological | innovative | production
On June 16th, the completion and commissioning celebration of Shengsi Biotechnology Shanghai Innovation Drug Production Base was held in Zhangjiang, Shanghai. Officials from relevant departments such as the Shanghai Municipal Commission of Economy and Information Technology, Pudong New Area, Zhangjiang Science City, Zhangjiang Group, Xinchang Town, Shanghai Biomedical Industry Association, and representatives of corporate shareholders attended the event together.
According to reports, Shengsi Bio has long been committed to becoming the world's leading biopharmaceutical company in the field of hemophilia treatment. At present, the R & D team has started the development of more innovative products in the field of hemophilia. This time, Shengsi Biology has invested 0.5 billion yuan to complete the construction of Shengsi Biology's Shanghai innovative drug production base. It has a 2 × 500L, a 2 × 2000L stock solution production line, a sterile freeze-dried preparation production line and a perfect production quality management system. It adopts international advanced equipment and leading technology to carry out clinical drug use and commercial product production of independent innovative drugs, the annual production of up to 10 billion units of various types of long-acting recombinant coagulation factors. Up to now, we have completed mechanical and electrical decoration, equipment installation and commissioning, environmental verification, and successfully completed the 117 product "re-coagulation and safety".®"Ultra-long-acting recombinant coagulation factor eight engineering production, and has started clinical phase III clinical drug production.
The completion and operation of Shengsi Biotechnology Shanghai Innovative Drug Production Base marks the completion of the company's entire innovative drug industry chain of "early research, pilot production, and sales". Wang Yali, Chairman of Shengsi Biotechnology, introduced: "Shengsi Biotechnology Shanghai Innovative Drug Production Base will become an important support point for the company to explore the forefront of medicine and promote the progress of biopharmaceutical technology, providing innovative therapies and drugs for more patients to meet clinical needs. The completion and production of the base is a key milestone event for the company's evolution from a biotechnology enterprise to a biopharmaceutical enterprise. In the future, the company will increase research and development investment, continuously expand its research and development advantages in the global hemophilia field, and expand into metabolic diseases and anti-tumor fields."
On that day, four innovative long-acting recombinant clotting factor drugs from Shengsi Biotechnology were simultaneously released during the clinical and industrial stages. As the only enterprise in China dedicated to the development of a full range of therapeutic drugs for hemophilia, Shengsi Biological's four long-acting recombinant coagulation factor products have entered different stages of industrialization and clinical application. With the launch of these four Class 1 innovative biological drugs, it will break the situation where there is no long-acting recombinant clotting factor available in China, and improve the accessibility and compliance of patient medication; At the same time, with the progressiveness technology and the synergistic advantages of series of products, more and better choices are brought to more than one million patients worldwide, so that patients can not only relieve their pain, but also live a normal life.